First Human Gets Cell-Reversing Gene Therapy for Blindness

Scientists just took a massive leap toward turning back the biological clock inside our bodies.

Life Biosciences, a Boston-based biotechnology company, has administered the first ever anti-aging gene therapy to a human patient. The treatment, called ER-100, aims to restore vision in people suffering from serious eye diseases by literally rejuvenating their damaged cells.

The therapy works by using three special proteins that act like a reset button on aging cells. These proteins, called OSK factors, restore cells to a younger state without changing a person's DNA sequence.

Think of it like this: your DNA stays the same throughout life, but the instructions for which genes turn on or off change over time due to aging, disease, and lifestyle choices. This therapy resets those harmful changes that build up over decades.

The science behind this approach won a Nobel Prize in 2012. Researchers discovered they could turn ordinary cells back into stem cells using these same factors, proving that cellular aging isn't necessarily permanent.

Life Biosciences is testing ER-100 on patients with two serious eye conditions: open-angle glaucoma and NAION, sometimes called a mini-stroke of the optic nerve. Both diseases cause progressive vision loss, and current treatments can't reverse the damage already done.

"Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage," said David Sinclair, co-founder of Life Biosciences and Harvard Medical School professor. The key word there is "not irreversible."

After successful tests in rodents and primates, the therapy has now entered Phase 1 clinical trials to assess whether it's safe for humans.

The Ripple Effect

The eye might just be the beginning. Life Biosciences is already developing a second therapy targeting liver disease and exploring applications for other organs throughout the body.

Several other companies are racing toward similar breakthroughs. Retro Biosciences, backed by OpenAI's Sam Altman, aims to add ten healthy years to human lifespan. Cambridge-based Shift Bioscience is using the same mechanism to tackle age-driven diseases.

What makes this moment special isn't just one patient receiving one treatment. It's proof that scientists are moving from theory to reality, from lab dishes to living people.

The therapy still faces years of testing before it could become widely available. But the first step has been taken, and that step represents decades of research finally reaching human hands.

For millions living with vision loss and age-related diseases, this trial offers something powerful: evidence that cellular aging might not be a one-way street after all.